Back to Planning Applications
DISCO PA/2018/852
Applications for discharge of conditions are not open to public consultation and the Local Planning Authority will only accept responses from persons/organisations that have been formally consulted and requested to provide comments.
Application Details
Reference
PA/2018/852
Proposal
Application to discharge conditions attached to planning permission PA/2016/1777
Relating to
PA/2016/1777
Details of conditions to discharge
The details within the Phase 1 Desk Study and Phase 2 Interpretative Report are acceptable; this condition is hereby partly discharged. The condition cannot be discharged in full until the development is completed as it covers any contamination not previously identified.
Condition
9.
No development shall commence until an assessment of the risks posed by any contamination, carried out in accordance with British Standard BS 10175: Investigation of potentially contaminated sites - Code of Practice and the Environment Agency’s Model Procedures for the Management of Land Contamination (CLR 11) (or equivalent British Standard and Model Procedures if replaced), shall have been submitted to and approved in writing by the local planning authority. If any contamination is found, a report specifying the measures to be taken, including the timescale, to remediate the site to render it suitable for the approved development shall be submitted to and approved in writing by the local planning authority. The site shall be remediated in accordance with the approved measures and timescale and a verification report shall be submitted to and approved in writing by the local planning authority. If, during the course of development, any contamination is found which has not been previously identified, work shall be suspended and additional measures for its remediation shall be submitted to and approved in writing by the local planning authority. The remediation of the site shall incorporate the approved additional measures and a verification report for all the remediation works shall be submitted to the local planning authority within an agreed timescale following the report’s completion and approval in writing by the local planning authority.
No development shall commence until an assessment of the risks posed by any contamination, carried out in accordance with British Standard BS 10175: Investigation of potentially contaminated sites - Code of Practice and the Environment Agency’s Model Procedures for the Management of Land Contamination (CLR 11) (or equivalent British Standard and Model Procedures if replaced), shall have been submitted to and approved in writing by the local planning authority. If any contamination is found, a report specifying the measures to be taken, including the timescale, to remediate the site to render it suitable for the approved development shall be submitted to and approved in writing by the local planning authority. The site shall be remediated in accordance with the approved measures and timescale and a verification report shall be submitted to and approved in writing by the local planning authority. If, during the course of development, any contamination is found which has not been previously identified, work shall be suspended and additional measures for its remediation shall be submitted to and approved in writing by the local planning authority. The remediation of the site shall incorporate the approved additional measures and a verification report for all the remediation works shall be submitted to the local planning authority within an agreed timescale following the report’s completion and approval in writing by the local planning authority.
Related Documents
| Document Type | Description | Date | |
|---|---|---|---|
| Application Form | Download | 26 April 2018 | |
| Decision Notice | Parts 1-3 | 29 June 2020 | |
| Supporting Document | Phase 1 Desk Study Report | 26 April 2018 | |
| Supporting Document | Phase 2 Interpretative Report | 26 April 2018 |
Comments
| Type | Name | Date | |
|---|---|---|---|
| Consultation Reply | Environmental Health (Commercial) | 19 October 2018 |